6.75
+0.15
+(2.27%)
At close: April 15 at 8:05:43 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
105,757
105,757
113,450
102,290
89,587.24
Cost of Revenue
3,884
3,884
4,636
4,793
4,020.80
Gross Profit
101,873
101,873
108,814
97,497
85,566.43
Operating Expense
85,644
85,644
89,601
88,294
55,432.92
Operating Income
16,229
16,229
19,213
9,203
30,133.51
Net Non Operating Interest Income Expense
1,547
1,547
1,044
726
259.96
Other Income Expense
5,442
5,442
-97,222
-517
-788.66
Pretax Income
23,218
23,218
-76,965
9,412
29,604.81
Tax Provision
5,320
5,320
8,515
5,098
6,168.24
Net Income Common Stockholders
12,085
12,085
-92,933
2,302
23,436.56
Diluted NI Available to Com Stockholders
12,085
12,085
-92,933
2,302
23,436.56
Basic EPS
-1.04
0.14
-1.41
0.03
0.31
Diluted EPS
-1.04
0.05
-1.41
0.03
0.31
Basic Average Shares
85,769.53
85,094.95
65,831.68
76,583.62
76,583.62
Diluted Average Shares
85,769.53
102,293.53
65,831.68
76,583.62
76,583.62
Total Operating Income as Reported
16,163
16,163
-67,230
9,203
--
Total Expenses
89,528
89,528
94,237
93,087
59,453.73
Net Income from Continuing & Discontinued Operation
12,085
12,085
-92,933
2,302
23,436.56
Normalized Income
6,611.07
6,611.07
-17,326.84
2,302
23,246.79
Interest Income
1,547
1,547
1,044
707.75
382.33
Interest Expense
--
--
--
43.34
122.37
Net Interest Income
1,547
1,547
1,044
726
259.96
EBIT
16,229
16,229
19,213
9,203
29,727.18
EBITDA
17,817
17,817
20,327
10,332
31,655.29
Reconciled Cost of Revenue
3,884
3,884
4,636
4,793
4,020.80
Reconciled Depreciation
1,588
1,588
1,114
1,129
1,928.12
Net Income from Continuing Operation Net Minority Interest
12,085
12,085
-92,933
2,302
23,436.56
Total Unusual Items Excluding Goodwill
7,101
7,101
-95,704
--
239.72
Total Unusual Items
7,101
7,101
-95,704
--
239.72
Normalized EBITDA
10,716
10,716
116,031
10,332
31,415.57
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,627.07
1,627.07
-20,097.84
--
49.95
12/31/2021 - 1/5/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
D01.BE BELITE BIO INC. R
51.50
+1.98%
87S.MU Roivant Sciences Ltd
8.90
+1.78%
BH3.SG PTC Therapeutics Inc
38.80
+4.86%
9LB.DU Legend Biotech Corp
30.20
+7.09%
BH3.BE PTC Therapeutics Inc
41.20
+3.52%
87S.DU Roivant Sciences Ltd
8.78
-1.35%
DUL.SG Alnylam Pharmaceuticals Inc
209.60
-0.33%
ATQP.SG Vericel Corp
37.00
+2.21%
6XC.F Soleno Therapeutics, Inc.
59.15
+4.51%
41X.SG Ardelyx Inc
4.0540
-0.86%